Part: 12         Session: 123456789101112131415161718192021222324252627282930313233343536         Page 595596597598599600601602603604605606607608610611612613614615616617618619620621622623624625626 of 1143

absolutely delighted, and we've had a very happy payoff from my point of view in that while the National Heart Institute is taking a very long time about establishing clinical trials to confirm the usefulness of Premarin against arteriosclerosis in men who have had heart attacks--the work which has been shown by Dr. Marmaston and her group at the University of Southern California and the work of Katherine Stamler at Michael Reese in Chicago. While their work, which has shown with less than a thousand cases that deaths are out in half, at least, as a result of the usefulness of Premarin, the Veterans Administration, under the leadership of Dr. Schnapper and Dr. Huber, is attempting to confirm it now and they are building up a caseload at Veterans Hospital a now with patients on Premarin to confirm, or to deny if they find that it doesn't work, the work of these two groups, with which I've had so much to do in terms of support, that is, that the Foundation has supported.

Now, if they confirm the usefulness of Premarin, there's no doubt that it will be used throughout the world and that the average length of life for people who have had heart attacks will be increased and perhaps there'll be a prolongation of life as a result of this because Premarin is an inexpensive bill which can be taken daily and doesn't involve any complicated injection or anything like that, as for instance streptomycin did and does. So that, I'm still hoping that we'll get more funds to aid the Veterans Administration in doing more and better clinical research, but we've only been moderately successful so far.